Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (Nasdaq: QTRX) appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics, effective June 4, 2026.
He will lead Diagnostics strategy, initially focused on Alzheimer’s disease diagnostics, reporting to the CEO and joining the Executive Leadership Team.
Albrecht previously managed about $2.9 billion in revenue as Regional Vice President at Quest Diagnostics and brings extensive experience in commercial leadership, partnerships, operations, and governance.
Quanterix (Nasdaq: QTRX) announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, from June 8-10, 2026.
CEO Everett Cunningham will join a fireside chat on June 9 at 1:20 pm ET, with a live webcast and replay available on the company’s investor relations website.
Quanterix (NASDAQ: QTRX) granted an inducement equity award to new Chief Operating Officer Anthony Catalano on May 15, 2026. The award consists of 141,330 RSUs under the 2025 Inducement Plan, vesting in four equal annual installments, and was approved under Nasdaq Rule 5635(c)(4).
Quanterix (Nasdaq: QTRX) announced a planned transition of its Chief Financial Officer, Vandana Sriram. She will remain CFO through June 15, 2026 to support continuity while a search for her successor is underway.
According to Quanterix, the company is on solid financial footing, with a stated path to cash flow breakeven and synergy targets, supported by cost discipline and cash management.
Quanterix (NASDAQ: QTRX) reported Q1 2026 revenue of $36.4M (up 20% year‑over‑year) and ended the quarter with $102.6M in cash, cash equivalents, marketable securities, and restricted cash. GAAP gross margin was 42.7% and adjusted gross margin was 50.9%. Adjusted EBITDA loss narrowed to $9.8M. The company cites realized synergies from the Akoya acquisition, reiterated full‑year 2026 revenue guidance of $169–$174M, expects GAAP gross margin 41–45% and adjusted gross margin 49–53%, and anticipates cash‑flow breakeven in H2 2026 with year‑end cash near $100M and no debt.
Operationally, Quanterix announced collaborations with Tempus AI and Life Line Screening, PD‑BUILD participation, new assay and panel launches, and expects three clinical utility study completions plus an FDA 510(k) decision in H2 2026.
Lucent Diagnostics and Tempus AI (NASDAQ: TEM) announced a collaboration to integrate the LucentAD® Complete blood-based Alzheimer’s biomarker panel into Tempus Next care gap workflows and the Tempus clinical ordering platform.
The agreement makes LucentAD Complete available for neurologists to order via existing EHR integrations, aims to embed guideline-directed patient identification, and seeks to increase evaluation of patients eligible for approved Alzheimer’s treatments.
Quanterix (Nasdaq: QTRX) will report first quarter 2026 financial results and host a conference call on May 6, 2026 at 4:30 p.m. ET. A press release will be issued prior to the call after market close and posted on the company's website.
The live webcast will be accessible from the Investors Event Details page and an archived replay will be available for one year.
Quanterix (Nasdaq: QTRX) and PreludeDx announced that AidaBREAST is the first multi-omic assay to predict both 10-year locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
The validation included 922 HR+/HER2- patients with a median follow-up of ~10 years, and the test combines spatial proteomics on the Akoya PhenoImager HT platform with Opal chemistry plus targeted RNA sequencing. Findings will be presented at AACR Annual Meeting 2026 on April 21 at Quanterix booth 2028.
Quanterix (Nasdaq: QTRX) debuts its Content Innovation Engine at AACR 2026, integrating Akoya spatial biology with Quanterix SIMOA immunoassay expertise to accelerate translational and clinical spatial biology. New products and modules include the IO60 Spike-In Module, ADC high-plex content, PhenoCode Molecular Barcoding Kit (early access May 2026), and two ADC lung cancer panels available via Accelerator.
Quanterix will host live in-booth presentations April 20–21 and a large customer poster presence at AACR 2026.
Quanterix (NASDAQ: QTRX) announced its 2026 annual meeting of shareholders will be held virtually on June 9, 2026 at 10:00 AM ET. Stockholders of record as of April 14, 2026 may vote. The company set an April 6, 2026 deadline for shareholder proposals and director nominations.
Additional meeting details and proxy materials will be provided in the company's proxy statement.